How would you approach frontline treatment for a metastatic non-squamous NSCLC patient with MET amplification and a concurrent KRAS mutation?

There are a couple of components to this question: first, what is the role of TKI therapy in MET amplified lung cancer, and second, what is a clinician to do when there are more than one "driver" mutations (ie KRAS and MET amp in this case)? Regarding the first question, this is somewhat timely in that there are a couple of recent publications evaluating the utility of crizotinib as therapy in patients with MET amplification (Clin Cancer Res. 2019 Dec 15;25(24):7312-7319, Ann Oncol. 2019 Dec 1;30(12):1985-1991). Prior to these studies, the only data with an approved MET inhibitor that I was aware of was reported at ASCO 2018 (Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 9062-9062). All of these suggest that the response rate...